International Research Journal of Engineering and Technology (IRJET)
e-ISSN: 2395-0056
Volume: 10 Issue: 04 | Apr 2023
p-ISSN: 2395-0072
www.irjet.net
Analytical Methods Development And Validation For Estimation Of Rivastigmine Drug Used For Alzheimer’s Disease: A Systematic Review Ashwini R Walave 1, Hemlata S. Bhawar 2, Mayur S. Bhosale 3 1 Research schollar, Pravara Rural College of pharmacy, Pravaranagar, Maharashtra, India.
2 Professor, Dept. of Pharmaceutical Chemistry, Pravara Rural College of pharmacy, Pravaranagar, Maharashtra,
India.
3 Professor, Dept. of Pharmaceutical Chemistry, Pravara Rural College of pharmacy, Pravaranagar, Maharashtra,
India. ---------------------------------------------------------------------***--------------------------------------------------------------------that carers go through is equally significant, and it has an Abstract - Quality assurance and quality control of
impact on their physical and emotional health. In low to middle income and high income nations, respectively, barely 5-10% and 40–50% of individuals have gotten a formal diagnosis of AD, in spite of its societal impact.[19]
pharmaceutical formulations and bulk pharmaceuticals both heavily rely on pharmaceutical analysis. The demand for innovative analytical techniques has increased as a result of the pharmaceutical industries' rapid expansion and medication production across the globe. Development of analytical methods has therefore evolved into the core function of analysis. Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive memory defeat and impairment in behaviour, language, and visuospatial skills. Rivastigmine is a carbamate-derived acetylcholine esterase inhibitor that is primarily used to treat mild to moderate Alzheimer's disease. The primary goal of this review was to highlight spectrophotometric, reverse phase high performance liquid chromatography (RP-HPLC), high-performance liquid chromatography (HPLC), high-performance thin layer chromatography (HPTLC), and liquid chromatography-mass spectroscopy (LC-MS) techniques that can be used for method development and validation for Rivastigmine drug . The review is a collection of information that includes the various analytical techniques used, the various columns used, the mobile phase used, flow rate, various detectors, and detection wavelength and retention time. The purpose of this review is to stimulate research into the creation of new, more accurate, precise, and specific methods for estimation of rivastigmine.
It is believed that Dr. Alois Alzheimer, a German psychiatrist and neuropathologist, first described the dementing illness that subsequently came to be recognised as AD. [5] The financial cost of Alzheimer's disease (AD) is among the highest in the world. 50 million people worldwide were estimated to have Alzheimer's disease in 2019.[14]
Key Words: Alzheimer’s disease, Rivastigmine, Dementia, techniques.
Method
development,
Analytical
Fig 1.1 The hallmarks of Alzheimer's disease (AD), a neurodegenerative disorder, are neuritic plaques and neurofibrillary tangles in the medial temporal lobe and neocortical regions of the brain. Clinically, the disease shows up as a gradual decline in cognitive and behavioural abilities. Dementia, the most common form of the illness, already affects 50 million people globally, and by 2050, experts expect that number to increase to 152 million cases, doubling every five years.[4] Dementia is a clinical condition (a collection of related signs and symptoms) that is characterised by a steady decline in mental capacity.
1.INTRODUCTION Alzheimer's disease (AD) is the most prevalent serious neurocognitive impairment in the world today, affecting up to 47 million individuals. It is the sixth most common cause of death in the US, accounting for 29.4 fatalities per 100,000 people, according to the most recent statistics from the Centers for Disease Control and Prevention (CDC). cardiovascular disease deaths have fallen by 14% between 2000 and 2014, whereas complications from AD have shot up by 89% during the same period. The stress
© 2023, IRJET
|
Impact Factor value: 8.226
|
ISO 9001:2008 Certified Journal
|
Page 465